Finance

Lists
KPTI:NASDAQ
Karyopharm Therapeutics Inc
၀.၆၀ US$
+၀.၈၃%
(+၀.၀၀၅၀) 1D
၀.၆၁ US$
+၀.၄၁% (+၀.၀၀၂၅)
After hours
Closed: အောက် ၉, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KPTI...
Open
၀.၆၀ US$
High
၀.၆၃ US$
Low
၀.၅၆ US$
Mkt. cap
၁.၃၇ ကုဋေ
Avg. vol.
၁.၄၆ သန်း
Volume
၉.၆၃ သိန်း
52-wk high
၁၀.၉၉ US$
52-wk low
၀.၅၆ US$
EPS
-၁၂.၈၄ US$
Beta
၁.၀၄
Shares outstanding
၂.၂၇ ကုဋေ
No. of employees
၂၂၈
Open
၀.၆၀ US$
High
၀.၆၃ US$
Low
၀.၅၆ US$
Mkt. cap
၁.၃၇ ကုဋေ
Avg. vol.
၁.၄၆ သန်း
Volume
၉.၆၃ သိန်း
52-wk high
၁၀.၉၉ US$
52-wk low
၀.၅၆ US$
EPS
-၁၂.၈၄ US$
Beta
၁.၀၄
Shares outstanding
၂.၂၇ ကုဋေ
No. of employees
၂၂၈
News stories
From web sources and news partners
Kalkine Media
Kalkine Media
·
ပြီးခဲ့သည့် ၂၂ မိနစ်
Why Does Strategy (NASDAQ:MSTR) Matter After the Rebound?
Detroit Free Press
Detroit Free Press
·
ပြီးခဲ့သည့် ၇ နာရီ
How an S&P 500 high, then some reality checks hit markets this week
About Karyopharm Therapeutics Inc
CEO-
Employees၂၂၈
Founded၂၀၀၈
HeadquartersNewton, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to KPTI in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for KPTI in the last 3 months.
Highest
Current ၀.၆၀ US$
၁၁.၀၀ US$ (+၁,၇၁၈.၁၈%)
Average
၆.၅၄ US$ (+၉၈၀.၉၉%)
Lowest
၃.၀၀ US$ (+၃၉၅.၈၇%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Maintained
၃.၆၈ US$
+၅၀၈.၃%
09/01/2026
Brian Abrahams
RBC Capital
Buy
Maintained
၈.၀၀ US$
+၁,၂၂၂.၃%
08/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
၁၁.၀၀ US$
+၁,၇၁၈.၂%
07/31/2026
Colleen M. Kusy
Robert W. Baird
Hold
Downgraded
-
-
07/31/2026
Edward Tenthoff
Piper Sandler
Buy
Maintained
၇.၀၀ US$
+၁,၀၅၇%
07/31/2026
Robert Burns
H.C. Wainwright
Hold
Downgraded
၃.၀၀ US$
+၃၉၅.၉%
07/31/2026
Unknown Analyst
Leerink Partners
Hold
Reiterated
၇.၀၀ US$
+၁,၀၅၇%
05/15/2026
Michael King
Rodman & Renshaw
Buy
Initiated
၂၈.၀၀ US$
+၄,၅၂၈.၁%
03/09/2026
Last report
၂၀၂၆ ဩ ၁၃
Fiscal period
Q2 2026
-၂.၃၂ US$ / -၁.၃၉ US$
-၆၆.၉၁%miss
Revenue / Est. (USD)
၃.၃၄ ကုဋေ / ၃.၂၂ ကုဋေ
+၃.၈၅%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၄.၄၀ ကုဋေ
၃.၄၁ ကုဋေ
၃.၅၁ ကုဋေ
၃.၃၄ ကုဋေ
Cost of goods sold
၃.၂၇ ကုဋေ
-၉.၆၅ ကုဋေ
၃.၅၁ ကုဋေ
၃.၀၀ ကုဋေ
Cost of revenue
၃.၂၇ ကုဋေ
-၉.၆၅ ကုဋေ
၃.၅၁ ကုဋေ
၃.၀၀ ကုဋေ
Research and development expenses
-
၁၂.၅၆ ကုဋေ
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၂.၆၆ ကုဋေ
၂.၂၈ ကုဋေ
၂.၆၇ ကုဋေ
၂.၅၉ ကုဋေ
Operating expense
၂.၆၆ ကုဋေ
၁၄.၈၄ ကုဋေ
၂.၆၇ ကုဋေ
၂.၅၉ ကုဋေ
Total operating expenses
၅.၉၃ ကုဋေ
၅.၁၉ ကုဋေ
၆.၁၈ ကုဋေ
၅.၆၀ ကုဋေ
Operating income
-၁.၅၂ ကုဋေ
-၁.၇၈ ကုဋေ
-၂.၆၈ ကုဋေ
-၂.၂၅ ကုဋေ
Other non operating income
-၇.၄၂ သန်း
-၁.၀၀ ကုဋေ
၁.၆၄ ကုဋေ
-၃.၂၁ ကုဋေ
EBT including unusual items
-၃.၃၁ ကုဋေ
-၁၀.၂၃ ကုဋေ
-၂.၂၄ ကုဋေ
-၆.၇၀ ကုဋေ
EBT excluding unusual items
-၃.၃၁ ကုဋေ
-၃.၉၉ ကုဋေ
-၂.၂၄ ကုဋေ
-၆.၇၀ ကုဋေ
Income tax expense
၃.၄၀ သောင်း
-၆.၇၀ သောင်း
၁.၀၀ ထောင်
-
Effective tax rate
-၀.၁၀%
၀.၀၇%
-
-
Other operating expenses
-
-
-
-
Net income
-၃.၃၁ ကုဋေ
-၁၀.၂၂ ကုဋေ
-၂.၂၄ ကုဋေ
-၆.၇၀ ကုဋေ
Net profit margin
-၇၅.၂၁%
-၂၉၉.၈၉%
-၆၃.၈၆%
-၂၀၀.၄၈%
Earnings per share
-၃.၈၂
-၂.၂၃
-၁.၂၄
-၂.၃၂
Interest and investment income
၅.၅၃ သိန်း
၆.၀၇ သိန်း
၅.၁၁ သိန်း
၇.၂၂ သိန်း
Interest expense
-၁.၁၀ ကုဋေ
-၁.၂၆ ကုဋေ
-၁.၂၆ ကုဋေ
-၁.၃၁ ကုဋေ
Net interest expenses
-၁.၀၅ ကုဋေ
-၁.၂၀ ကုဋေ
-၁.၂၀ ကုဋေ
-၁.၂၄ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
-၁.၅၁ ကုဋေ
-၁.၇၈ ကုဋေ
-၂.၆၇ ကုဋေ
-၂.၂၅ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ